Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.

An expert discusses how rilzabrutinib’s covalent reversible binding mechanism provides a favorable safety profile with only manageable grade 1 to 2 toxicities and no cardiovascular or bleeding ...

SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet counts in heavily pretreated patients with immune thrombocytopenia (ITP), ...

Immune thrombocytopenia (ITP) is an autoimmune disease in which IgG antiplatelet antibodies accelerate platelet clearance and reduce platelet production. The prevalence of ITP is approximately 1 to 3 ...

Immune thrombocytopenia (ITP) is a rare condition that causes a low platelet count. People with ITP can experience life threatening bleeding if the condition is not treated. Many people with ITP go ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW ORLEANS -- ...

Adzynma is a purified recombinant form of the ADAMTS13 protein designed to replace the missing or deficient ADAMTS13 enzyme. The Food and Drug Administration (FDA) has approved Adzynma for ...